

Areas of Interest for Third Party Research Proposals

Hematology-Oncology

REGN5458 (BCMA x CD3 bispecific antibody)

Non-interventional IIS in Plasma Cell Dyscrasias exploring:

- Biomarkers leading to better characterization, management, and treatment options
 - BCMA expression pre and post treatment (standard of care agents or novel agents)
 - Early disease progression and/or mechanisms of resistance
 - T cell phenotyping in biopsy and aspirate
 - Plasma cell markers associated with progression/resistance to standard of care
 - Immune subset characterization including T cell suppressive mechanisms
 - Biomarkers for future therapeutic target development
 - Biomarkers of Plasma Cell Dyscrasias
- Models to assess functional immune responsiveness to BCMA x CD3
- Experimental models to explore novel combinations with BCMA x CD3